The University of Montpellier publishes an article devoted to Prof. Jamal Tazi and the company Abivax, developer of the drug obefazimod, highlighting the contribution of the IGMM and CNRS to the project.
The article looks back on 20 years of research, the creation of Abivax, and the development of this promising treatment for chronic inflammatory bowel diseases, presented as a notable example of a successful public–private partnership.
